Back to results
US 2024/0252671 A1Published application
Neodegrader-anti-cd33 antibody conjugates
AssigneeOrum Therapeutics Inc.
InventorsNathan FISHKIN, Peter U. PARK, Chen BAI
Life of this patent
Estimating the term…
Abstract
The present disclosure provides neoDegraders conjugated to anti-CD33 antibodies. Also provided are compositions comprising the conjugates. The compounds and compositions are useful for treating a disease or condition, e.g., cancer, in a subject in need thereof.
Claims61
A conjugate of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein:
- a is an integer from 1 to 10;
- A is phenyl or a C4-C10cycloalkyl ring;
- U is selected from NH and CF2;
- R1 is independently selected from hydrogen and halo;
- X is selected from —NR2—, ═C(CH3)—, -Q-(CH2)n—, and -Q(CH2)mQ′(CH2)n—;
- wherein
- Q and Q′ are each independently O, S, or N(R2)v;
- v is 1 or 2;
- each R2 is independently hydrogen or C1-C6alkyl;
- n is an integer from 1 to 6;
- and
- m is an integer from 2 to 6;
- wherein the left side of each group is attached to L and the right side is attached to A;
- provided that when X is NH or -Q-(CH2)n—, R1 is halo;
- L is a cleavable linker or non-cleavable linker;
- and
- Bm is an anti-CD33 antibody or antigen-binding portion thereof comprising a heavy chain variable region (VH) complementarity determining region (CDR) 1 (VH-CDR1) comprising the amino acid sequence as set forth in SEQ ID NO:
- 1, a VH-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
- 2, a VH-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
- 3, a light chain variable region (VL) CDR1 (VL-CDR1) comprising the amino acid sequence as set forth in SEQ ID NO:
- 5, a VL-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
- 6, and a VL-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
- 7.
21 more elements
A conjugate of formula (V):
- or a pharmaceutically acceptable salt thereof, wherein Bm is an anti-CD33 antibody or antigen-binding portion thereof comprising a VH-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:
- 1, a VH-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
- 2, a VH-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
- 3, a VL-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:
- 5, a VL-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
- 6, and a VL-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
- 7.
4 more elements
A conjugate of formula (VI):
- or a pharmaceutically acceptable salt thereof, wherein Bm is an anti-CD33 antibody or antigen-binding portion thereof comprising a VH-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:
- 1, a VH-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
- 2, a VH-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
- 3, a VL-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:
- 5, a VL-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
- 6, and a VL-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
- 7.
4 more elements
A conjugate of formula (VII):
- or a pharmaceutically acceptable salt thereof, wherein Bm is an anti-CD33 antibody or antigen-binding portion thereof comprising a VH-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:
- 1, a VH-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
- 2, a VH-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
- 3, a VL-CDR1 comprising the amino acid sequence as set forth in SEQ ID NO:
- 5, a VL-CDR2 comprising the amino acid sequence as set forth in SEQ ID NO:
- 6, and a VL-CDR3 comprising the amino acid sequence as set forth in SEQ ID NO:
- 7.
4 more elements
Dependencies are inferred from the claim text.